Phagocytosis of apoptotic cells, also called efferocytosis, is an essential feature of immune responses and critical for the resolution of inflammation. Plasma and tissue levels of plasminogen activator inhibitor-1 (PAI-1), an inhibitor of fibrinolysis, are elevated in inflammatory conditions, including sepsis and acute lung injury, in which activated neutrophils accumulate in tissues and contribute to organ dysfunction. In this study, we explored the potential involvement of PAI-1 in modulating neutrophil efferocytosis. We found enhanced phagocytosis of viable PAI-1 deficient (PAI-1 ؊/؊ ) and of wild-type neutrophils treated with anti-PAI-1 antibodies. PAI-1 levels were decreased on the surface of apoptotic neutrophils and the enhanced phagocytosis of apoptotic wild-type neutrophils or of viable PAI-1 ؊/؊ neutrophils was diminished by preincubation with PAI-1. The increased phagocytosis associated with PAI-1 deficiency or blockade depended on both the lipoprotein receptor-related protein (LRP) and its ligand, calreticulin (CRT), because the LRP-mediated increase in phagocytosis of viable neutrophils induced by blockade of CD 47 was abrogated by PAI-1. CRT levels are increased on viable PAI-1 ؊/؊ neutrophils. While CRT colocalizes with PAI-1 on viable neutrophils, markedly diminished colocalization of PAI-1 and CRT was present on apoptotic neutrophils. Our data therefore indicate that PAI-1 serves as a novel ''don't eat me'' signal for viable and apoptotic neutrophils.
P
hagocytosis of apoptotic cells, also known as efferocytosis, occupies an important role in normal tissue homeostasis and regulation of immune responses (1) (2) (3) . Rapid clearance of dying cells prevents leakage of potentially cytotoxic or antigenic contents into the extracellular milieu and the resultant initiation of inflammatory processes and tissue injury (4) . Defects or delays in apoptotic corpse elimination have been closely associated with autoimmune and inflammatory diseases, such as systemic lupus erythematosus and acute lung injury (5) (6) (7) .
Apoptotic cells are marked by a number of alterations in various cell surface molecules. One of the major changes on the cell surface during apoptosis is appearance of phosphatidylserine (PtdSer) (5) . PtdSer is recognized and bound by PtdSer receptors through opsonins, a group of soluble molecules in the extracellular milieu, including milk-fat globule EGF-factor 8 (MFG-E8), growth arrestspecific gene 6 (Gas6), and thrombospondin, that serve as bridges between PtdSer and cell surface receptors on phagocytes, such as integrins and Mer family type I receptor tyrosine kinases (8) (9) (10) . Calreticulin (CRT) has recently been found to mediate efferocytosis through binding to the low-density lipoprotein related protein (LRP) on phagocytes (1, 11) . However, in contrast to PtdSer, CRT is also expressed on viable cells, which raises the question of how living cells can resist inadvertent uptake. At least a partial response to this dilemma relates to CD47, an integrin associated protein that binds to SIRP␣, inducing its phosphorylation in phagocytes and subsequent inhibition of phagocytosis (1) . In addition, another integrin associated protein, CD31, has been shown to block viable cell ingestion (12) . At present, CD31 and CD47 are the only ''don't eat me'' signals described for viable cells.
PAI-1 is a member of the serine protease inhibitor (SERPIN) superfamily (13) . The primary molecules to which PAI-1 binds are urokinase-type plasminogen activator (uPA), tissue-type plasminogen activator (tPA), fibrin, vitronectin, and members of the low density lipoprotein receptor (LRP) family (13, 14) . Elevated serum and tissue levels of PAI-1 have been found in a number of inflammatory diseases, including myocardial infarction, sepsis, and acute lung injury, with increased circulating PAI-1 levels being associated with unfavorable outcomes (15) (16) (17) (18) . Previous studies suggested that microvascular thrombosis associated with inhibition of fibrinolytic processes by PAI-1 and the role of PAI-1 as a chemotactic factor promoting the migration of lymphocytes and neutrophils into inflammatory sites contributed to its inflammatory effects (19) (20) (21) . In addition, PAI-1 also appears to have intrinsic proinflammatory properties by potentiating Toll-like receptor 4 (TLR4) mediated activation of neutrophils (22) .
Considering the critical role that phagocytosis of neutrophils and other activated cell populations occupies in the resolution of inflammation and the significant contribution of PAI-1 to inflammatory progression, we examined the possibility that PAI-1 might modulate neutrophil efferocytosis. Quite unexpectedly, we found that PAI-1 functions as a novel don't eat me signal and is required for viable neutrophils to avoid ingestion. PAI-1 can also function to inhibit the engulfment of apoptotic neutrophils by macrophages.
Results

PAI-1 Deficiency Is Associated with Enhanced Phagocytosis of Viable
Neutrophils. We first examined uptake of viable and apoptotic mouse neutrophils by mouse peritoneal macrophages. As shown in Fig. 1A , there was a significantly higher phagocytic index for apoptotic neutrophils compared with that found for viable neutrophils. However, viable neutrophils from transgenic mice lacking PAI-1, i.e., PAI-1 Ϫ/Ϫ , also demonstrate increased ingestion by macrophages to levels comparable with those present for apoptotic wild-type (WT) cells (Fig. 1B) . Viable PAI-1 Ϫ/Ϫ neutrophils have the same levels of staining for annexin V as do viable WT neutrophils [supporting information (SI) Fig. S1A ], indicating that the increase in phagocytosis is not caused by altered cell viability, but indeed is due to PAI-1 deficiency. We next determined whether blockade of PAI-1 on the neutrophil surface affects the phagocytosis of viable neutrophils in a manner similar to that seen with PAI knockout cells. As shown in Fig. 1C , preincubation of viable WT neutrophils with rabbit anti-PAI-1 antibodies resulted in significantly increased phagocytosis. To confirm this effect, we used mouse anti-PAI-1 monoclonal antibodies and found that preincubation of viable WT neutrophils with mouse anti-PAI-1 monoclo-nal antibodies also enhanced their engulfment by macrophages (Fig. S1B) . There was no change in phagocytosis of viable PAI-1 Ϫ/Ϫ neutrophils after incubation with anti-PAI-1 antibodies (Fig. 1C) , further establishing that the increase in phagocytosis of viable WT neutrophils after treatment with anti-PAI-1 antibodies is PAI-1-dependent.
The increased phagocytosis of viable PAI-1 Ϫ/Ϫ neutrophils suggests a role for cell surface associated PAI-1 in the regulation of efferocytosis. To examine this issue, we incubated viable PAI-1 Ϫ/Ϫ neutrophils with exogenous PAI-1 protein and then determined whether such pretreatment affected the phagocytic index. As shown in Fig. 1D , uptake of viable PAI-1 Ϫ/Ϫ neutrophils was dosedependently inhibited by exposure to PAI-1 and was decreased to basal levels after incubation with 1 g/ml PAI-1. Of note, similar or greater concentrations of PAI-1 are found in serum and tissues of patients with inflammatory conditions, such as acute lung injury (15) (16) (17) (18) . These data suggest that binding of PAI-1 to viable PAI-1 Ϫ/Ϫ neutrophils blocks their phagocytosis.
To determine whether PAI-1 deficiency leads to increased phagocytosis of neutrophils by macrophages under in vivo conditions, viable WT or PAI-1 Ϫ/Ϫ neutrophils were intratracheally injected into WT mice. As shown in Fig. 1E , there was a significant increase in the phagocytosis of PAI-1 Ϫ/Ϫ neutrophils by alveolar macrophages compared with that found after administration of WT cells into the lungs. Preincubation of PAI-1 Ϫ/Ϫ neutrophils with PAI-1 protein, but not with mouse albumin, before intratracheal administration decreased the phagocytic index to levels similar to those seen with injection of WT neutrophils (Fig. 1F ).
LRP Participates in PAI-1 Associated Modulation of Neutrophil Phago-
cytosis. LRP is a major receptor for PAI-1 and participates in efferocytosis through binding to CRT, a major ''eat me'' signal on target cells (1) . We therefore examined whether LRP was involved in the PAI-1 associated modulation of neutrophil phagocytosis. As shown in Fig incubation with anti-PAI-1 antibodies was reversed by pretreatment of macrophages with anti-LRP antibodies or RAP (Fig. S2 ). CD47 is a major don't eat me signal on the surface of viable cells (1) . Loss of CD47 induces the uptake of viable cells through mechanisms that involve interaction of LRP and CRT (1) . Because of the involvement of LRP in modulating PAI-1 associated effects on phagocytosis, we determined whether PAI-1 is able to affect the increase in phagocytosis that normally occurs after CD47 blockade. As shown in Fig. 2B , exposure to PAI-1 inhibited the enhanced neutrophil engulfment produced by CD47 blockade, indicating that PAI-1 can modulate LRP/CRT-dependent efferocytosis. Anti-CRT antibodies also abrogated the increase in phagocytosis produced by CD47 blockade, consistent with previous studies (1).
Suppression of Phagocytosis by PAI-1 Does Not Require ProteaseInhibiting Nor LRP-Binding Activity, but Does Involve Binding to
Vitronectin. Although the above experiments indicated that LRP is involved in PAI-1 mediated reduction of neutrophil phagocytosis, they did not establish whether direct interaction of PAI-1 with LRP was required for this effect. To examine this question, and the requirement for PAI-1's protease inhibitory activity, in modulating phagocytosis of viable neutrophils, we preincubated viable neutrophils with the PAI-1 mutants R76E, which is unable to bind to LRP, or R346A, which is incapable of inhibiting protease activity (23) , and then determined the phagocytic index. Both of these PAI-1 mutants were as effective as wild-type PAI-1 in inhibiting the enhanced phagocytosis of PAI-1 Ϫ/Ϫ neutrophils or of WT neutrophils preincubated with anti-CD47 antibodies (Fig. 3A and Fig. S3 ). These results suggest that LRP binding and protease inhibition are not essential for the ability of PAI-1 to block macrophage uptake of viable neutrophils.
In vivo, most circulating PAI-1 is bound to vitronectin (Vn) (24) (25) (26) . We therefore examined whether Vn participates in modulating the effects of PAI-1 on phagocytosis. As shown in Fig. 3B , the Vn-binding deficient mutants, PAI-1 (R101A), PAI-1 (Q123K), and PAI-1 (R101A/Q123K) all lost the ability to inhibit the enhanced phagocytosis of PAI-1 Ϫ/Ϫ neutrophils, indicating that binding of PAI-1 to Vn is necessary for the inhibitory effects of PAI-1 on efferocytosis. As our experiments demonstrated that PAI-1 is a potent don't eat me signal for viable neutrophils, it was also possible that PAI-1 might participate in modulating phagocytosis of apoptotic cells. In initial studies, we performed confocal microscopy to examine the distribution of PAI-1 on viable and apoptotic neutrophils. As shown in Fig. 4A , large amounts of PAI-1 are present on the membrane of viable neutrophils. In contrast, the levels of PAI-1 on the apoptotic neutrophils are dramatically decreased. These results were confirmed by flow cytometry analysis of neutrophil associated PAI-1 staining (Fig. 4B) . These data suggest that changes in the amount of PAI-1 on the apoptotic cell surface may contribute to the enhanced engulfment of apoptotic cells by phagocytes.
PAI-1 Levels
Because there are diminished amounts of PAI-1 on apoptotic neutrophils, it was possible that restoration of membrane associated PAI-1 would inhibit phagocytosis of apoptotic neutrophils. To examine this issue, apoptotic neutrophils were preincubated with PAI-1. As shown in Fig. 4C , exposure of apoptotic neutrophils to PAI-1 significantly decreased their uptake by macrophages. Consistent with previous studies, blockade of LRP on the engulfing cells with either anti-LRP antibodies or RAP also diminished the phagocytosis of apoptotic neutrophils. To demonstrate that PAI-1 does bind to apoptotic neutrophils, we labeled PAI-1 protein with fluorescent dye. As shown in Fig. 4D . the annexin V positive (apoptotic) neutrophils demonstrated increased PAI-1 binding after incubation with PAI-1. In contrast, there was no increase in binding of a control protein, mouse albumin, to the surface of apoptotic neutrophils. Incubation of viable neutrophils with labeled PAI-1 did not demonstrate any increase in PAI-1 binding, suggesting that saturating amounts of PAI-1 are present on the surface on viable cells. Similar to findings with viable neutrophils, LRP binding and protease inhibiting activities of PAI-1 are not required for its inhibitory activities on neutrophil phagocytosis, as shown by decrease in the phagocytic index by PAI-1 mutants unable to bind LRP (i.e., R76E) or lacking protease activity (i.e., R346A) (Fig. S4) .
CRT Is Involved in PAI-1 Associated Modulation of Neutrophil Phagocytosis.
Our experiments demonstrated that even though LRP is involved in increased phagocytosis of viable PAI-1 Ϫ/Ϫ cells, LRPbinding activity is not required for PAI-1 to inhibit this increase in phagocytosis. We therefore decided to examine whether PAI-1 exerts its anti-phagocytic effects through modifying expression of the LRP ligand, CRT. We found that CRT levels on the surface of viable PAI-1 Ϫ/Ϫ neutrophils are increased compared with those on WT cells (Fig. 5A) . Furthermore, incubation of viable PAI-1 Ϫ/Ϫ neutrophils with PAI-1 protein decreased surface CRT to levels similar to those on WT cells (Fig. 5A) . These data suggest that elevated levels of CRT may contribute, at least in part, to the increase in phagocytosis of viable PAI-1 Ϫ/Ϫ neutrophils. We also examined whether PAI-1 regulates levels of the don't eat me signal CD47 on neutrophils. In contrast to the relationship between PAI-1 and CRT expression, there was no difference in CD47 expression on the surface of viable WT and PAI-1 Ϫ/Ϫ neutrophils (Fig. 5B) .
Although we found that CRT is increased on the surface of PAI-1 Ϫ/Ϫ neutrophils and that neutrophil exposure to PAI-1 decreases CRT levels on PAI-1 Ϫ/Ϫ cells, these alterations in CRT expression are relatively modest and may be insufficient mechanisms for the anti-phagocytic effects of PAI-1. Therefore, we examined the distribution of PAI-1 and CRT on the surfaces of viable and apoptotic neutrophils. We found that PAI-1 colocalizes with CRT on viable cells, suggesting that PAI-1 could affect recognition and/or binding of CRT by its receptor, LRP (Fig. 5C) . PAI-1 levels were dramatically decreased on the surface of apoptotic neutrophils (Fig. 4 A and B and 5C ), but were still visible after increasing the pinhole of the green fluorescence. In contrast to staining of living cells, the patterns for both CRT and PAI-1 became punctuate on apoptotic neutrophils (Fig. 5C ). In addition, whereas there was colocalization of PAI-1 and CRT on viable cells, there was very little overlap of PAI-1 and CRT staining on apoptotic neutrophils.
Discussion
In the present study, we found that PAI-1 has a novel role in the phagocytosis of neutrophils, acting as a don't eat me signal for viable and apoptotic cells. Because apoptotic cell clearance is critical to the resolution of inflammation, our data suggest that PAI-1 may exacerbate inflammatory responses by blocking the clearance of apoptotic neutrophils, thereby allowing such neutrophils to become necrotic and to release their intracellular contents into the extracellular milieu. Our findings, together with previous studies demonstrating that PAI-1 enhances LPS induced neutrophil activation (22) and promotes the migration and infiltration of lymphocytes and neutrophils into inflammatory sites (19) (20) (21) 27) , demonstrate that PAI-1 has multiple proinflammatory roles that are independent of its participation in coagulation and microvascular thrombosis. We found that the enhanced neutrophil phagocytosis associated with PAI-1 deficiency can be abrogated by blocking LRP on macrophages with anti-LRP antibodies or the LRP-specific blocking peptide RAP, indicating that LRP participates in PAI-1 mediated modulation of efferocytosis. In addition, the increase in neutrophil phagocytosis produced by blockade of CD47, which has been demonstrated to be LRP-dependent, is prevented by exposure to PAI-1. These data support a role for LRP in PAI-1-regulated phagocytosis. However, the LRP-binding deficient PAI-1 mutant, R76E, inhibits the phagocytosis of viable PAI-1Ϫ/Ϫ neutrophils to a similar extent as does wild-type PAI-1, indicating that binding between LRP and PAI-1 is not required for the inhibitory effects of PAI-1 on neutrophil uptake. Previous studies have shown that LRP mediates viable cell phagocytosis through binding to CRT on the target cell surface (1). Thus, blocking either LRP on the engulfing cells or CRT on the target cells can have similar effects in reducing efferocytosis. Although the PAI-1 R76E mutant cannot directly bind to LRP on the target cell surface, it can still potentially affect the recognition and binding of CRT on the target cells by phagocyte associated LRP through interactions with uPAR, integrins, membrane associated vitronectin, and/or other yet-to-beidentified ligands on the target cell surface. Indeed, PAI-1 mutants that are unable to bind to vitronectin, unlike wild type PAI-1, have no effect on the increased phagocytosis of PAI-1 Ϫ/Ϫ neutrophils, indicating that interactions between vitronectin and PAI-1 are required to mediate the inhibitory effects of PAI-1 on neutrophil engulfment by macrophages. These results suggest that vitronectin may participate in regulating interactions between PAI-1, CRT, and LRP in a manner similar to that described for its role in modulating clearance of thrombin and PAI-1 complexes by LRP (28).
We found that PAI-1 colocalizes with CRT on the surface of viable, but not apoptotic neutrophils, providing a potential mechanism involving PAI-1 mediated inhibition of CRT-LRP interactions through which PAI-1 could regulate CRT-mediated ingestion of viable cells and contribute to the resistance of living cells to inadvertent ingestion. In addition, CRT is increased on viable PAI-1 (Ϫ/Ϫ) neutrophils, suggesting an additional mechanism for the enhanced phagocytosis of viable PAI-1 (Ϫ/Ϫ) cells. Of note, incubation of PAI-1 Ϫ/Ϫ neutrophils with PAI-1 resulted in return of the increased CRT concentrations on the cell membrane to baseline levels, indicating that the inhibitory effects of PAI-1 on neutrophil phagocytosis may be indirect, and occur, in part, through regulating levels of CRT on viable neutrophils.
We found that PAI-1 levels on the surface of apoptotic neutrophils are dramatically decreased. If the mechanism through which PAI-1 acts as a don't eat me signal is by regulating interactions of CRT with LRP, then the loss of membrane associated PAI-1 in apoptotic cells would lead to enhanced CRT mediated uptake of these cells. Support for this hypothesis comes from the finding that the colocalization of PAI-1 and CRT found on viable neutrophils was disrupted on the apoptotic cell surface, indicating that even the low levels of PAI-1 on apoptotic neutrophils are unable to prevent recognition and binding of CRT by LRP, thus contributing to the increase in the phagocytosis of apoptotic cells. Together, these data suggest that there may be more than one mechanism by which PAI-1 can inhibit phagocytosis of apoptotic neutrophils.
Tissue and circulating PAI-1 levels remain elevated for prolonged periods in acute inflammatory conditions, such as sepsis or acute lung injury, that are associated with massive accumulation of activated neutrophils into the lungs and other organs (15, 16) . Therefore, modulation of PAI-1 expression on activated neutrophils may be of clinical benefit through enhancing neutrophil clearance and resolution of inflammation in injured organs. 
